NASDAQ:ESPR - Esperion Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Esperion Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $33.98 -1.31 (-3.71 %) (As of 03/31/2020 03:30 AM ET) Add Compare Today's Range$33.33Now: $33.98▼$35.6450-Day Range$27.44MA: $50.44▼$73.8452-Week Range$24.82Now: $33.98▼$76.98Volume600,221 shsAverage Volume879,767 shsMarket Capitalization$934.86 millionP/E RatioN/ADividend YieldN/ABeta1.85 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Esperion Therapeutics, Inc., a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination pill, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study. Esperion Therapeutics, Inc. was founded in 2008 and is headquartered in Ann Arbor, Michigan.Read More Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ESPR Previous Symbol CUSIPN/A CIK1434868 Webhttp://www.esperion.com/ Phone734-887-3903Debt Debt-to-Equity Ratio0.06 Current Ratio3.20 Quick Ratio3.20Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$148.36 million Price / Sales6.30 Cash FlowN/A Price / Cash FlowN/A Book Value$0.73 per share Price / Book46.55Profitability EPS (Most Recent Fiscal Year)($3.59) Net Income$-97,170,000.00 Net Margins-65.49% Return on Equity-98.94% Return on Assets-38.29%Miscellaneous Employees76 Outstanding Shares27,512,000Market Cap$934.86 million Next Earnings Date5/13/2020 (Estimated) OptionableOptionable Receive ESPR News and Ratings via Email Sign-up to receive the latest news and ratings for ESPR and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:ESPR Rates by TradingView Esperion Therapeutics (NASDAQ:ESPR) Frequently Asked Questions How has Esperion Therapeutics' stock been impacted by COVID-19 (Coronavirus)? Esperion Therapeutics' stock was trading at $42.93 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ESPR stock has decreased by 20.8% and is now trading at $33.98. View which stocks have been mosted impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Esperion Therapeutics? 12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Esperion Therapeutics in the last year. There are currently 5 hold ratings, 6 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Esperion Therapeutics. When is Esperion Therapeutics' next earnings date? Esperion Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, May 13th 2020. View our earnings forecast for Esperion Therapeutics. How were Esperion Therapeutics' earnings last quarter? Esperion Therapeutics Inc (NASDAQ:ESPR) issued its earnings results on Thursday, February, 27th. The biopharmaceutical company reported ($2.26) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($2.67) by $0.41. The biopharmaceutical company had revenue of $0.98 million for the quarter, compared to the consensus estimate of $0.99 million. Esperion Therapeutics had a negative net margin of 65.49% and a negative return on equity of 98.94%. Esperion Therapeutics's revenue was up 9819999999.0% on a year-over-year basis. During the same quarter in the previous year, the company earned ($2.24) earnings per share. View Esperion Therapeutics' earnings history. What price target have analysts set for ESPR? 12 analysts have issued twelve-month target prices for Esperion Therapeutics' stock. Their forecasts range from $45.00 to $191.00. On average, they anticipate Esperion Therapeutics' share price to reach $90.73 in the next year. This suggests a possible upside of 167.0% from the stock's current price. View analysts' price targets for Esperion Therapeutics. What are Wall Street analysts saying about Esperion Therapeutics stock? Here are some recent quotes from research analysts about Esperion Therapeutics stock: 1. According to Zacks Investment Research, "Esperion announced encouraging fourth quarter results, wherein earnings and revenues beat estimates. The company received approval for its two drugs, Nexletol and Nexlizet, in February 2020, which was a major boost. The company plans to launch Nexletol in March and Nexlizet in July. Regulatory applications seeking approval for these drugs are under review in Europe. Both candidates have achieved significant reduction in elevated LDL-C levels in hypercholesterolemia patients. The targeted area represents a significant opportunity. Shares have outperformed the industry in the past year. However, Esperion is heavily dependent on the successful commercialization of Nexletol and Nexlizet. The company will likely face stiff competition as its drugs target a crowded market. Esperion also has no other pipeline candidates." (3/26/2020) 2. Stifel Nicolaus analysts commented, "We are reiterating our Buy rating and lowering our target price to $70 which reflects a more conservative pre-CVOT BPA/combo sales ramp and higher SG&A assumptions. Even with our more conservative forecasts, we believe ESPR is undervalued at these levels (EV of ~$700 million) as we think the stock continues to reflect investor skepticism on the commercial opportunity for BPA/ combo and the company’s cash runway. We view BPA/combo as a clinically de-risked asset with two upcoming and believe BPA’s CVOT design portends a high probability of success. Further, our recent KOL checks have been consistent with our past discussions (see deep dive) in validating what we believe is a meaningful commercial opportunity for BPA/combo in the statin intolerant population." (9/17/2019) 3. Northland Securities analysts commented, "We are now modeling $0.69 in non-GAAP EPS on $97.8 million in revenue for FY/19." (8/29/2019) Has Esperion Therapeutics been receiving favorable news coverage? Media coverage about ESPR stock has trended somewhat negative this week, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Esperion Therapeutics earned a coverage optimism score of -1.4 on InfoTrie's scale. They also assigned news headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the next several days. View the latest news aboutEsperion Therapeutics. Are investors shorting Esperion Therapeutics? Esperion Therapeutics saw a drop in short interest in the month of March. As of March 13th, there was short interest totaling 6,209,100 shares, a drop of 9.4% from the February 27th total of 6,850,000 shares. Based on an average daily trading volume, of 862,900 shares, the days-to-cover ratio is presently 7.2 days. Currently, 23.8% of the shares of the stock are short sold. View Esperion Therapeutics' Current Options Chain. Who are some of Esperion Therapeutics' key competitors? Some companies that are related to Esperion Therapeutics include Evotec (EVTCY), Mirati Therapeutics (MRTX), BridgeBio Pharma (BBIO), Nektar Therapeutics (NKTR), Global Blood Therapeutics (GBT), Blueprint Medicines (BPMC), FibroGen (FGEN), Zai Lab (ZLAB), Arrowhead Pharmaceuticals (ARWR), Emergent Biosolutions (EBS), GW Pharmaceuticals PLC- (GWPH), Genmab A/S (GMAB), PPD (SDGR), PTC Therapeutics (PTCT) and Ultragenyx Pharmaceutical (RARE). What other stocks do shareholders of Esperion Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Esperion Therapeutics investors own include Alon USA Partners (ALDW), Targa Resources (TRGP), Navios Maritime Partners (NMM), Ship Finance International (SFL), NVIDIA (NVDA), Micron Technology (MU), BioMarin Pharmaceutical (BMRN), Alibaba Group (BABA), Gilead Sciences (GILD) and NXP Semiconductors (NXPI). Who are Esperion Therapeutics' key executives? Esperion Therapeutics' management team includes the following people: Mr. Timothy M. Mayleben M.B.A., Pres, CEO & Director (Age 58)Dr. Narendra D. Lalwani, Exec. VP of R&D (Age 66)Mr. Richard B. Bartram, CFO & Corp. Sec. (Age 37)Mr. Alexander Duke Schwartz, Sr. Director of Investor RelationsMs. Marianne Andreach, Sr. VP What is Esperion Therapeutics' stock symbol? Esperion Therapeutics trades on the NASDAQ under the ticker symbol "ESPR." How do I buy shares of Esperion Therapeutics? Shares of ESPR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Esperion Therapeutics' stock price today? One share of ESPR stock can currently be purchased for approximately $33.98. How big of a company is Esperion Therapeutics? Esperion Therapeutics has a market capitalization of $934.86 million and generates $148.36 million in revenue each year. The biopharmaceutical company earns $-97,170,000.00 in net income (profit) each year or ($3.59) on an earnings per share basis. Esperion Therapeutics employs 76 workers across the globe. View additional information about Esperion Therapeutics. What is Esperion Therapeutics' official website? The official website for Esperion Therapeutics is http://www.esperion.com/. How can I contact Esperion Therapeutics? Esperion Therapeutics' mailing address is 3891 RANCHERO DRIVE SUITE 150, ANN ARBOR MI, 48108. The biopharmaceutical company can be reached via phone at 734-887-3903 or via email at [email protected] MarketBeat Community Rating for Esperion Therapeutics (NASDAQ ESPR)Community Ranking: 2.8 out of 5 ( )Outperform Votes: 545 (Vote Outperform)Underperform Votes: 424 (Vote Underperform)Total Votes: 969MarketBeat's community ratings are surveys of what our community members think about Esperion Therapeutics and other stocks. Vote "Outperform" if you believe ESPR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ESPR will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 3/31/2020 by MarketBeat.com StaffFeatured Article: Are we seeing the beginning of a new bubble?
